Document:

Letter Agreement

 Exhibit 10.60 

 

			
	

	  	 Maria Harris

Counsel,
 Pharmaceuticals,
Europe

	  
	  

 April 20, 2010 
 Norwich Pharmaceuticals, Inc. 
 6826 State Highway 12 

Norwich, NY 13815 
 Attention: Christopher R.
Calhoun, President 
 Dear Mr. Calhoun: 
 Reference is made to the Contract Manufacturing Services Agreement between Procter & Gamble Pharmaceuticals, Sarl (“PGP”) and Norwich Pharmaceuticals, Inc., dated
January 30, 2006, as amended on July 11, 2006 (the “Agreement”). Capitalized terms used herein but not defined herein shall have the meaning assigned to such terms in the Agreement. 

As you may be aware, in a transaction that closed on October 30, 2009 (the “Transaction”), The Procter & Gamble Company
sold its global prescription pharmaceuticals business, including PGP, to Warner Chilcott PLC (“Warner Chilcott”). As a result of the Transaction, PGP became a wholly-owned subsidiary of Warner Chilcott. In connection with such
Transaction, we will assign the Agreement to Warner Chilcott Company, LLC, an Affiliate of PGP, effective May 1, 2010. As a result, on and after May 1, 2010, Warner Chilcott Company, LLC will be the counterparty to the Agreement and PGP
will no longer be a party to the Agreement (the “Assignment”). 
 The parties hereto acknowledge and agree that Agreement shall
be amended as follows: 
  

	 	•	 	 All references to “Procter & Gamble Pharmaceuticals, Sarl” shall be replaced with references to “Warner Chilcott Company,
LLC” and references to “P&G” shall be replaced with references to “Warner Chilcott”, 

  

	 	•	 	 Section 3.12 of the Agreement is amended by deleting the text and replacing such text with the following: 

““Product(s)” means the products listed on Schedule A and any other products agreed to in writing by the parties
from time to time.”, 
  

	 	•	 	 Section 9 of the Agreement is amended by deleting the text and replacing such text with the following: 

“9. FAILURE TO PERFORM: In the event Warner Chilcott requests performance of Contract Manufacturing Services hereunder and NPI is
unable or unwilling to perform said Contract Manufacturing Services for reason(s) within NPI Control, or should NPI consistently and continually fail to meet Warner Chilcott’s quantity requirements, or NPI consistently fails to meet NPI’s
Product Specifications, manufacturing standards, standards for quality assurance or release procedures, or should NPI fail to perform as described in Article 5.3 or 
 100 Enterprise Drive n Rockaway, New Jersey 07866 
 Phone: (973) 442-3378        Fax: (973) 442-3310        800-521-8813 

 

 

  

 Article 6.8, or NPI experiences a significant quality systems failure including but not
limited to receipt of an FDA warning letter or its Territory equivalent, Warner Chilcott has the unequivocal right, upon notice, to enter NPI’s Norwich Plant for the sole purpose of conducting an inspection and audit and NPI agrees to cooperate
with Warner Chilcott in this event by making NPI personnel available to Warner Chilcott and its personnel. In addition, notwithstanding the provisions of Section 4.3, Warner Chilcott shall be free to purchase all or any portion of its Product
requirements from any available source, or to move production into another of NPI’s facilities or to an alternate contract manufacturer should NPI fail to perform or should Warner Chilcott anticipate a failure to perform as evidenced by
objective criteria and measures of performance for NPI required Contract Manufacturing Services hereunder. Warner Chilcott will provide NPI with a 10 business days notice of such an anticipated failure to perform and the opportunity to avoid or
correct in a manner acceptable to Warner Chilcott such anticipated failure to perform.” 
  

	 	•	 	 Section 34 of the Agreement is amended by deleting the P&G Notice information and replacing such text with the following:

 “Warner Chilcott Company, LLC 
 100 Enterprise Drive 
 Rockaway, NJ 07866 

Attention: General Counsel” 

Except as specifically set forth herein, nothing contained herein is intended to, or shall be deemed to, alter, amend or modify any of the rights or
obligations of the parties under the Agreement. This letter agreement shall be construed in accordance with and governed by the laws of the State of New York, without regard to the conflicts of laws rules thereof. 

Please acknowledge the Assignment and your acceptance of, and agreement with, the terms of this letter agreement by executing this letter agreement in
the spaces set forth below. 
  

	
	Very truly yours,
	
	 /s/ Maria Krasnikow Harris

	Maria Krasnikow Harris
	Counsel, Pharmaceuticals, Europe

 100
Enterprise Drive n Rockaway, New Jersey 07866 
 Phone: (973)
442-3378        Fax: (973) 442-3310        800-521-8813 

  

 Acknowledged and Agreed: 
 Norwich Pharmaceuticals, Inc. 
  

			
	By:	 	 /s/ Authorized Representative

		 	Name:
		 	Title:

 100 Enterprise Drive n Rockaway, NJ 07866 
 Phone: 973-442-3200 Fax: 973-442-3362 

 Schedule A 
  

			
	  
 95090001
 58046417
 95365063
 98758655
 98777035
	  	Actonel 5 mg
		
	95089953
 58046411
 95272350
	  	Actonel 30 mg
		
	95090003
 95010514
 95365211
	  	Actonel 35 mg
		
	95053234
 98575582
	  	Actonel 150 mg
		
	95912056	  	Actonel 75 mg
	95945042	  	Asacol UK 800mg printed
	98578979	  	Libertas 35 mg
	80077003	  	Actonel 30mg 30’s Canada Trade
	15893454	  	Didronel 200 mg Gran Export
	15857838	  	Didronel 400 mg Gran Export
	15823051	  	Didronel 400 mg Gran
	15121219	  	Full Service Bulk Calcium sold to Europe

100 Enterprise Drive n Rockaway, NJ 07866 

Phone: 973-442-3200 Fax: 973-442-3362Letter Agreement

 Exhibit 10.61 
 CONFIDENTIAL TREATMENT REQUESTED UNDER 
 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 240.24b-2.

 [*****] INDICATES OMITTED MATERIAL THAT IS THE 
 SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST 
 FILED SEPARATELY WITH THE COMMISSION. 

THE OMITTED MATERIAL HAS BEEN FILED 
 SEPARATELY
WITH THE COMMISSION. 

 

 

 December 21, 2010 
 Norwich Pharmaceuticals, Inc. 
 6826 State Highway 12 

Norwich, NY 13815 
 Attention: Christopher R.
Calhoun, President 
 Dear Mr. Calhoun: 
 Reference is made to the Contract Manufacturing Services Agreement between Warner Chilcott Company, LLC (“Warner Chilcott”) and Norwich Pharmaceuticals, Inc., (“NPI”)
dated January 30, 2006, as amended on July 11, 2006 and April 20, 2010 (the “Agreement”). Capitalized terms used herein but not defined herein shall have the meaning assigned to such terms in the Agreement.

 This letter will serve to amend the above referenced Agreement. The effective date of this amendment shall be July 1, 2011. 

The parties hereto acknowledge and agree that Agreement shall be amended as follows: 

 

	 	•	 	 References throughout the Agreement to “SLEA” or “Service Level Execution Agreement” shall be replaced by references to
“Partnership Agreement(s)”. 

  

	 	•	 	 Add a new Section 6.9 as provided below: 

 “6.9. Quality Assurance Technical Agreement. As soon as practicable, the parties shall enter into a quality agreement to address quality assurance and cGMP roles and responsibilities.”

  

	 	•	 	 Section 11.1 of the Agreement is amended by deleting the text and replacing such text with the following: 

“The Term of this Agreement (“Term”) begins July 1, 2011 and ends December 3l, 2014, unless terminated
earlier pursuant to the terms contained in this Agreement.” 
  

	 	•	 	 Section 12.2.1 of the Agreement is amended by deleting the text and replacing such text with the following: 

“Section 12.2.1 Pricing: Prices are firm through June 30, 2011. Thereafter, NPI may request a price change for the period
beginning July 1, 2011 through December 3l, 2011, and thereafter annually as of January 1 of each year. The annual change in the Purchase Price shall not exceed the [*****] measured from the previous 12 month period. Further
adjustments may be made in accordance with this Agreement to account for changes in the quantity of Products to be supplied or applicable batch size. Also, Purchase Price adjustments may occur upon modifications to the Specifications requested by
either party pursuant to this Agreement. 
  

	 	•	 	 Section 12.2.2 of the Agreement is deleted in its entirety. 

 

	 	•	 	 Section 16 of the Agreement is amended by deleting the text and replacing such text with the following: 

Union Street, Road 195, Km. 1.1, Fajardo, Puerto Rico 00738 
 Phone: (787) 863-1850 Fax: (787) 863-6355 

 “Section 16. Compliance with Laws and Safety Measures: 

NPI represents and warrants that it is and will, and that the Products and Contract Manufacturing Services (including after being
incorporated into any finished products) are and will, at all times, be in full compliance with all applicable laws, regulations, rules, judgments, orders and decrees, including, without limitation, those related to intellectual property, customs,
labor, employment, working conditions, board of health, environmental matters, and cGMP. In addition, both NPI and Warner Chilcott shall each be responsible for ensuring that all of the suppliers of Materials that they purchase from, respectively,
maintain compliance with cGMP. NPI also represents and warrants that it has obtained and will maintain all licenses, consents and permits required to perform lawfully this Agreement. NPI assumes sole responsibility for taking all necessary health
and safety precautions for producing Products on behalf of Warner Chilcott pursuant to this Agreement. These precautions include, without limitation, such things as proper control of ventilation, the wearing of adequate protective clothing,
installation, and proper utilization of appropriate environmental control equipment. NPI will inform Warner Chilcott of any regulatory agency inspection, such as an OSHA inspection, which involves Warner Chilcott Products or the Contract
Manufacturing Services to produce these Products. NPI is responsible for any audit follow-up or response. Warner Chilcott will provide NPI information Warner Chilcott possesses which is needed by NPI to respond to such audits. In addition, NPI
agrees to provide Warner Chilcott with copies of any audit reports for audits conducted by such regulatory agencies, and for audits that NPI conducts of any suppliers of Materials, upon request, provided, however, that NPI shall be permitted to
redact any such reports to remove references or information not related to the Warner Chilcott Products or Contract Manufacturing Services.” 
  

	 	•	 	 Section 26 of the Agreement is amended by deleting the text and replacing such text with the following: 

Section 26. Assignment: 
 Notwithstanding the provisions of Article 23, neither NPI nor Warner Chilcott may assign its rights or delegate or subcontract this Agreement or its obligations pursuant hereto to any Third Party without
the prior written consent of the other; provided, however, Warner Chilcott may so assign or delegate to any of its Affiliates without NPI’s prior consent, and provided that if all or substantially all of the assets of Warner Chilcott are sold
to a Third Party, Warner Chilcott may assign its rights and obligations under this Agreement to such Third Party. If Warner Chilcott sells any of the Products to a Third Party, then Warner Chilcott may assign its rights and obligations regarding
such Product(s) under this Agreement to such Third Party with the agreement of NPI, such agreement not to be unreasonably withheld. 
 Except as
specifically set forth herein, nothing contained herein is intended to, or shall be deemed to, alter amend or modify any of the rights or obligations of the parties under the Agreement. This letter agreement shall be construed in accordance with and
governed by the laws of the State of New York, without regard to the conflicts of laws rules thereof. 
 Please acknowledge your acceptance of,
and agreement with, the terms of this letter agreement by executing this letter agreement in the spaces set forth below. 
  

	
	Very truly yours,
	
	 /s/ Max A. Torres

	Max A. Torres
	V.P. and General Manager
	Business Operations

  
 2 

 Acknowledged and Agreed: 
 Norwich Pharmaceuticals, Inc. 
  

					
	By:	 	 /s/ Christopher R. Calhoun

		 	Name:	 	Christopher R. Calhoun
		 	Title:	 	President

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]